These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24503398)

  • 1. [The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis].
    Liu SY; Yang L; Zhang L; Zhang X; He YJ
    Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1018-22. PubMed ID: 24503398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.
    Lv QW; Zhang W; Shi Q; Zheng WJ; Li X; Chen H; Wu QJ; Jiang WL; Li HB; Gong L; Wei W; Liu H; Liu AJ; Jin HT; Wang JX; Liu XM; Li ZB; Liu B; Shen M; Wang Q; Wu XN; Liang D; Yin YF; Fei YY; Su JM; Zhao LD; Jiang Y; Li J; Tang FL; Zhang FC; Lipsky PE; Zhang X
    Ann Rheum Dis; 2015 Jun; 74(6):1078-86. PubMed ID: 24733191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
    Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB; Cheng TT; Chindalore V; Damjanov N; Burgos-Vargas R; Delora P; Zimany K; Travers H; Caulfield JP
    Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial.
    Jaimes-Hernández J; Meléndez-Mercado CI; Mendoza-Fuentes A; Aranda-Pereira P; Castañeda-Hernández G
    Reumatol Clin; 2012; 8(5):243-9. PubMed ID: 22763150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
    Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
    Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
    Mack ME; Hsia E; Aletaha D
    Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study).
    Wevers-de Boer K; Visser K; Heimans L; Ronday HK; Molenaar E; Groenendael JH; Peeters AJ; Westedt ML; Collée G; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2012 Sep; 71(9):1472-7. PubMed ID: 22402145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
    Yoo DH; Racewicz A; Brzezicki J; Yatsyshyn R; Arteaga ET; Baranauskaite A; Abud-Mendoza C; Navarra S; Kadinov V; Sariego IG; Hong SS; Lee SY; Park W
    Arthritis Res Ther; 2016 Apr; 18():82. PubMed ID: 27038608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.